Lunai Bioworks, Inc. (NASDAQ: LNAI) has taken legal action against alleged naked short sellers, filing a federal securities fraud lawsuit in Delaware. The company, represented by national law firms Dickinson Wright and Fox Rothschild, claims that unidentified traders engaged in a coordinated scheme to manipulate the trading of its common stock, in violation of SEC Regulation SHO.
The complaint details repeated failures to deliver shares, with one instance reaching 234.6 times the maximum baseline daily rate. According to the filing, failures to deliver allegedly represented 81.6% of the company's total outstanding shares during certain periods. The lawsuit also highlights extreme trading volumes that exceeded Lunai's available share count. On March 17, 2026, more than 554 million shares were traded, representing 15.3 times the company's outstanding shares. Similarly, over 100 million shares were traded on May 4, 2026.
Lunai is seeking compensatory and special damages, injunctive relief, and recovery of legal costs. Counsel for the company has indicated they will pursue expedited discovery to identify the unnamed defendants and seek emergency relief to halt any ongoing manipulative trading. The case underscores the ongoing battle between small-cap companies and short sellers, who often face accusations of market manipulation through practices like naked short selling.
This lawsuit is significant because it highlights the potential vulnerabilities of emerging biotech firms to trading abuses. Lunai, an AI-driven precision medicine platform, is developing cancer immunotherapies and biodefense countermeasures. Its platforms include Augusta, an AI-powered precision neurology platform, and a portfolio focused on central nervous system disorders. The company also pursues federal government contracts for national security and biodefense applications. For a company with promising technology, stock manipulation can undermine investor confidence and hinder its ability to raise capital for critical research and development.
The case is being led by Jacob S. Frenkel, Chair of Dickinson Wright's Government Investigations and Securities Enforcement Practice, and Sidney S. Liebesman, Senior Litigation Partner at Fox Rothschild in Wilmington, Delaware. The legal team's experience in securities fraud litigation is expected to be a key factor in pursuing the allegations.
For Lunai, the lawsuit represents a proactive step to protect its shareholders and ensure the integrity of its stock. If successful, it could deter future manipulative practices and set a precedent for other companies facing similar issues. The outcome may also draw attention to the broader regulatory environment surrounding short selling and the enforcement of SEC rules. As the case progresses, it will be watched closely by investors and industry observers alike. More details can be found in the full press release at https://ibn.fm/XFOLP.
